Aphakia Market Research Report Information: By Types (Primary, Secondary), Causes (Congenital Aphakia, Surgical Aphakia, Acquired Aphakia), Treatment (Spectacles, Contact Lenses, Intraocular Lens Implantation), End Users- Forecast Till 2032

Aphakia Market Scenario

The Aphakia Market is expected to reach USD 3.9 Billion by 2032 at 11.3% CAGR during the forecast period 2023-2032. Aphakia describes the absence or dislocation of the crystalline eye lens. It is the most commonly occurs due to the presence of diseases such as trauma and congenital conditions or after surgery for cataract removal. Increasing prevalence of diseases such as diabetes & trauma and increasing number of accident have boosted the market growth of the aphakia. According to World Health Organization (WHO), in 2014, 285 million people were visually impaired across the globe in which 246 million had low vision and 39 million were completely blind. Additionally, According to the WHO, 422 million people have diabetes and this number is increasing at the rate of 8.5%. Moreover, increasing geriatric population, rapidly developing healthcare sector, and increasing demand for the better treatment of the ophthalmic diseases fuel the market growth. On the other hand, the high cost of the surgery and limited availability of the treatment may slow the market growth.

Intended Audience

• Pharmaceutical and Biotechnological Companies


• Research and Development (R&D) Companies


• Ophthalmic Companies


• Hospitals and Clinics


• Academic Institutes and Universities

Sources: WHO, annual reports, press release, white paper, company presentation

Segmentations

The aphakia market has been segmented on the basis of types, causes, treatment, and end user.

On the basis of type, the aphakia market is segmented into primary, and secondary.

On the basis of cause, the aphakia market is categorized into congenital aphakia, surgical aphakia, acquired aphakia, and others. Acquired aphakia is further segmented into traumatic extrusion, posterior dislocation, couching, and other.

On the basis of treatment, the aphakia market is segmented into spectacles, contact lenses, intraocular lens implantation, refractive surgery, and others. The spectacles are sub-segmented into +10D, +3-4D, and other. Refractive surgery is further segmented into keratophakia, epikeratophakia, and hyperopic LASIK.

On the basis of end user, the aphakia market is segmented into hospitals, ophthalmic clinics, and others.

Regional AnalysisThe Americas dominates the aphakia market owing to the increasing prevalence of people with aphakia. It was estimated that 6.1 million (5.1%) of Americans have pseudophakia/aphakia. Additionally, well-developed technology, huge diabetic population, and strong government support for research & development will fuel the market growth.

Europe is the second leading market across the globe, which is followed by Asia Pacific. Availability of funds for research, huge geriatric population and government support for research & development will drive the market.

Asia Pacific is the fastest growing aphakia market due to the presence of rapidly growing economy, huge patient pool, increasing prevalence of ophthalmic diseases, and presence of huge geriatric population.

On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited availability of medical facilities, and poor political conditions in Africa.

Key PlayersSome of key the players in the aphakia market are Johnson & Johnson Services, Inc. (US), Ophtec BV (Netherland), Alcon Laboratories, Inc. (Switzerland‎), Bausch & Lomb (US), Carl Zeiss AG (Germany), Rayner Company (US), Bohus BioTech AB (Sweden), CooperVision, Inc. (US), Lifecore Biomedical, LLC (US), Aetna Inc. (US), Ciba Vision (Switzerland), and Menicon (Singapore).

Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation